Dabuzalgron
CAS No. 219311-44-1
Dabuzalgron ( Ro 115-1240 )
Catalog No. M22674 CAS No. 219311-44-1
Dabuzalgron is an orally active selective alpha-1A adrenergic receptor agonist used to treat urinary incontinence. Dabuzaron prevents cardiotoxicity caused by doxorubicin by maintaining mitochondrial function.Dabuzaron treatment increased ERK phosphorylation in a dose-dependent manner with an EC50 of 4.8 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 113 | In Stock |
|
10MG | 205 | In Stock |
|
25MG | 333 | In Stock |
|
50MG | 500 | In Stock |
|
100MG | 718 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDabuzalgron
-
NoteResearch use only, not for human use.
-
Brief DescriptionDabuzalgron is an orally active selective alpha-1A adrenergic receptor agonist used to treat urinary incontinence. Dabuzaron prevents cardiotoxicity caused by doxorubicin by maintaining mitochondrial function.Dabuzaron treatment increased ERK phosphorylation in a dose-dependent manner with an EC50 of 4.8 μM.
-
DescriptionDabuzalgron is an orally active selective alpha-1A adrenergic receptor agonist used to treat urinary incontinence. Dabuzaron prevents cardiotoxicity caused by doxorubicin by maintaining mitochondrial function.Dabuzaron treatment increased ERK phosphorylation in a dose-dependent manner with an EC50 of 4.8 μM. ERK1 / 2 activation helps Dabuzaron's cardioprotection. Dabuzaron (10 μM; 4 hours) protects NRVM from cell death caused by doxorubicin (DOX). Dabuzaren (10 μM; 4 hours) activation of α1A-AR alleviates the harmful effects of DOX on mitochondrial membrane potential and eliminates the activation of important elements of the apoptotic response to mitochondrial damage.Dabuzaron (10μg / kg; oral tube; twice daily; 7 consecutive days; C57B16J wild-type or α1A-AR gene knockout mice) treatment can prevent DOX cardiotoxicity by activating α1A-AR. Dabuzaron prevents mitochondrial function-related transcript reduction, up-regulates PGC1α, retains ATP content, and reduces oxidative stress in DOX-treated mouse hearts.
-
SynonymsRo 115-1240
-
PathwayAngiogenesis
-
TargetAdrenergic Receptor
-
Recptorα1A-adrenergic receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number219311-44-1
-
Formula Weight317.79
-
Molecular FormulaC12H16ClN3O3S
-
Purity>98% (HPLC)
-
SolubilityDMSO:25 mg/mL(78.67 mM)
-
SMILESCc1c(OCC2=NCCN2)ccc(Cl)c1NS(C)(=O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Beak J, et al. An Oral Selective Alpha-1A Adrenergic Receptor Agonist Prevents Doxorubicin Cardiotoxicity. JACC Basic Transl Sci. 2017 Feb;2(1):39-53.
molnova catalog
related products
-
Bupranolol
Bupranolol is an antagonist of β2-adrenergic receptor,and has been used for angina pectoris, hypertension, glaucoma, cardiac arrhythmia and as an antithrombotic.
-
Clenbuterol hydrochl...
Clenbuterol hydrochloride is a β2 adrenergic receptor agonist. It is a powerful bronchodilator withfat burning properties.
-
Oxymetazoline hydroc...
Oxymetazoline Hydrochloride is a selective alpha-1 agonist and partial alpha-2 agonist topical decongestant.Oxymetazoline is a selective alpha-1 agonist and partial alpha-2 agonist topical decongestant used in the form of Oxymetazoline hydrochloride.